Vial

INDIVIDUAL TEST 220

Hu (ANNA-1) Antibodies (IgG)

Indication

Suspicion of paraneoplastic syndrome

Sample material

Serum

  • Minim. volume: 0,5 mL

CSF

  • Minim. volume: 2,0 mL

Transport

Within Sweden

  • room temperature

International

  • cold

Method

Serum

  • Immunoblot/ Indirect immunofluorescence (IIF)

CSF

  • Immunoblot/ Indirect immunofluorescence (IIF)

According to Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes, anti-neuronal antibodies should be detected by at least two independent methods to be reliable. At Wieslab IIF and immunoblot are used.

Reference interval

Serum

  • Immunoblot: <5 negative
  • Indirect Immunofluorescence: <1:10 negative

Likvor

  • Immunoblot: negative
  • Indirect immunofluorescence: negative

Result

Serum

  • Immunoblot: results are reported as negative, borderline, or positive with an intensity value.
  • Indirect immunofluorescence (IIF): results are reported as negative or positive. Positive results will be titrated.

CSF

  • Immunoblot: results are reported as negative, borderline, or positive.
  • Indirect immunofluorescence (IIF): results are reported as negative or positive.

Interpretation

Antibodies against Hu are also called ANNA-1 (anti-neuron-specific cell nuclear antibodies) and occur in paraneoplastic subacute sensory neuronopathy and/or paraneoplastic encephalomyelitis. The antibody prevalence is strongly associated with small-cell lung cancer but can also be seen in other tumor types (e.g. breast cancer, Hodgkin's lymphoma, melanoma, ovarian cancer, testicular cancer, thymoma). Neurological symptoms can precede cancer diagnosis by up to 5 years. Antibodies against Hu are graded as High-risk antibodies with a frequency of 85% of underlying cancer and a positive result yield 3 points PNS score, according to Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

References

  • Lancaster E et al. Neurology. 2011. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. PMID: 21747075
  • Zuliani L et al. J Neurol Neurosurg Psychiatry. 2012. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. PMID: 22448032
  • Rosenfeld MR, Dalmau J. Neurol Clin. 2018. Paraneoplastic Neurologic Syndromes. PMID: 30072076
  • Balint B et al. Brain. 2018. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels, and pathophysiology. PMID: 29053777
  • Graus F et al. Neurol Neuroimmunol Neuroinflamm. 2021. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. PMID: 34006622
  • Scheper T et al, EUROLINE_WB allows reliable differentiation of autoantibodies against neural antigens in patients with paraneoplastic neurological syndrome, In: “From proteinomic to Molecular Epidemiology: Relevance of Autoantibodies”, 6th Dresden Symposium on Autoantibodies. 2002, Vol 3, 562-563
  • Garza M, Piquet AL. Front Neurol. 2021. Update in Autoimmune Movement Disorders: Newly Described Antigen Targets in Autoimmune and Paraneoplastic Cerebellar Ataxia. PMID: 34489848

Last updated: 2024-06-26

More information

This is an accredited test.
> Read more [.pdf]

Learn more about sampling.
> Read more

Download request forms

Neurology

Can't find what you're looking for? We are here to help

Vial

ENSKILD ANALYS 220

Hu (ANNA-1)-antikroppar (IgG)

Indikation

Misstanke om paraneoplastiskt syndrom

Provmaterial

Serum

  • Minim. volym: 0,5 mL

Likvor

  • Minim. volym: 2,0 mL

Transport

Inom Sverige

  • rumstemperatur

Internationellt

  • kylt

Metod

Serum

  • Immunoblot och Indirekt immunofluorescens (IIF)

Likvor

  • Immunoblot och Indirekt immunofluorescens (IIF)

Enligt Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes ska anti-neuronala antikroppar detekteras med minst två oberoende metoder för att anses tillförlitliga. På Wieslab används IIF och immunoblot.

Referensintervall

Serum

  • Immunoblot: <5 negativt
  • Indirekt Immunofluorescens: <1:10 negativt

Likvor

  • Immunoblot: negativt
  • Indirekt immunofluorescens: negativt

Resultat

Serum

  • Immunoblot: resultat anges som negativt, gränsvärde eller positivt med intensitetsvärde.
  • Indirekt immunofluorescens: resultat anges som negativt eller positivt. Positivt resultat titreras.

Likvor

  • Immunoblot: resultat anges som negativt, gränsvärde eller positivt.
  • Indirekt immunofluorescens: resultat anges som negativt eller positivt.

Tolkning

Antikroppar mot Hu kallas också ANNA-1 (anti-neuronspecifika cell nukleära antikroppar) och förekommer vid paraneoplastisk subakut sensorisk neuronopati och/eller paraneoplastisk encefalomyelit. Antikropparnas förekomst är starkt kopplat till småcellig lungcancer men kan även ses vid andra tumörformer (ex bröstcancer, Hodgkins lymfom, malignt melanom, ovariecancer, testikelcancer, tymom). Neurologiska symtom kan föregå cancerdiagnos med upp till 5 år. Antikropparna riktade mot Hu bedöms vara High-risk antibodies med en förekomst på 85% för en underliggande cancer och positivitet ger 3 poäng i PNS score enligt Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.

Referenser

  • Lancaster E et al. Neurology. 2011. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. PMID: 21747075
  • Zuliani L et al. J Neurol Neurosurg Psychiatry. 2012. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. PMID: 22448032
  • Rosenfeld MR, Dalmau J. Neurol Clin. 2018. Paraneoplastic Neurologic Syndromes. PMID: 30072076
  • Balint B et al. Brain. 2018. Movement disorders with neuronal antibodies: syndromic approach, genetic parallels, and pathophysiology. PMID: 29053777
  • Graus F et al. Neurol Neuroimmunol Neuroinflamm. 2021. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. PMID: 34006622
  • Scheper T et al, EUROLINE_WB allows reliable differentiation of autoantibodies against neural antigens in patients with paraneoplastic neurological syndrome, In: “From proteinomic to Molecular Epidemiology: Relevance of Autoantibodies”, 6th Dresden Symposium on Autoantibodies. 2002, Vol 3, 562-563
  • Garza M, Piquet AL. Front Neurol. 2021. Update in Autoimmune Movement Disorders: Newly Described Antigen Targets in Autoimmune and Paraneoplastic Cerebellar Ataxia. PMID: 34489848

Senast uppdaterat: 2024-06-26

Mer information

Detta är en ackrediterad analys.
> Läs mer [.pdf]

Mer information om provtagning.
> Läs mer

Ladda ner remiss

Neurologi

Hittar du inte vad du söker? Vi kan hjälpa till